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Key points

r Pancreatic β-cell dysfunction is hypothesized to be the significant determinant of gestational
diabetes pathogenesis, however pancreatic samples from patients are scarce.

r This study reports a novel mouse model of gestational glucose intolerance in pregnancy,
r
r

originating from previous nutrition restriction in utero, in which glucose intolerance was
restricted to late gestation as is seen in human gestational diabetes.
Glucose intolerance was attributed to reduced β-cell proliferation, leading to impaired
gestational β-cell mass expansion in maternal endocrine pancreas, in addition to reduced
glucose-stimulated insulin secretion.
This model reproduces some of the features of gestational diabetes and is suitable for testing safe
therapeutic interventions that increase β-cell mass during pregnancy and prevent or reverse
gestational glucose intolerance.

Abstract Gestational diabetes mellitus (GDM) is an increasingly prevalent form of diabetes
that appears during pregnancy. Pathological studies link a failure to adaptively increase maternal
pancreatic β-cell mass (BCM) in pregnancy to GDM. Due to the scarcity of pancreatic samples
from GDM patients, we sought to develop a novel mouse model for impaired gestational glucose
tolerance. Mature female C57Bl/6 mouse offspring (F1) born to dams fed either a control (C) or
low-protein (LP) diet during gestation and lactation were randomly allocated into two subsequent
study groups: pregnant (CP, LPP) or non-pregnant (CNP, LPNP). Glucose tolerance tests were
performed at gestational day (GD) 9, 12 and 18. Subsequently, pancreata were removed for
fluorescence immunohistochemistry to assess α-cell mass (ACM), BCM and β-cell proliferation.
An additional group of animals was used to measure insulin secretion from isolated islets at GD18.

Sandra Szlapinski received her Bachelor of Science (Honours) in Biology at Western University in London, Canada. She is now
a PhD student in the Department of Physiology and Pharmacology and is also in the collaborative program of Developmental
Biology at Western University. She is working with Dr. David Hill at Lawson Health Research Institute within St. Joseph’s Health
Care. Her thesis aims to elucidate the underlying mechanisms of pancreatic β-cell deficiency in gestational diabetes with the
ultimate goal of providing a therapeutic intervention to reverse this deficiency and reduce hyperglycaemia in pregnancy.
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LPP females displayed glucose intolerance compared to CP females at GD18 (P < 0.001). BCM
increased threefold at GD18 in CP females. However, LPP females had reduced BCM expansion
(P < 0.01) concurrent with reduced β-cell proliferation at GD12 (P < 0.05). LPP females also had
reduced ACM expansion at GD18 (P < 0.01). LPP islets had impaired glucose-stimulated insulin
secretion in vitro compared to CP islets (P < 0.01). Therefore, impaired glucose tolerance during
pregnancy is associated with a failure to adequately adapt BCM, as a result of reduced β-cell
proliferation, in addition to lower glucose-stimulated insulin secretion. This model could be used
to evaluate novel interventions during pregnancy to increase BCM or function as a strategy to
prevent/reverse GDM.
(Received 14 March 2019; accepted after revision 10 June 2019; first published online 17 June 2019)
Corresponding author S. K. Szlapinski: Lawson Health Research Institute, St Joseph’s Health Care, 268 Grosvenor St.,
London, ON, PO Box 5777 Stn B, London ON, Canada N6A 4V2. Email: sszlapin@uwo.ca

Introduction
Gestational diabetes mellitus (GDM) is a form of diabetes
that develops during pregnancy and regresses postpartum.
Between 3 and 20% of women develop GDM, depending
on their risk factors (Feig et al. 2018). GDM increases
the risk of the mother developing subsequent type 2
diabetes mellitus (T2DM) by up to 7-fold compared to
euglycaemic pregnancies (Melchior et al. 2017). For the
offspring, exposure to GDM in utero has been linked to
an increased risk of childhood obesity and development
of T2DM (Sauder et al. 2017).
GDM develops due to insufficient insulin secretion
during the relatively insulin-resistant state in pregnancy
(Barbour et al. 2007). The state of peripheral maternal
insulin resistance is most prominent during the third
trimester when placental growth hormone and placental
lactogen levels are highest (Handwerger & Freemark,
2000; Newbern & Freemark, 2011). This ensures normal
fetal development by maintaining trans-placental flux of
glucose to the fetus. Consequently, maternal euglycaemia
is normally maintained through adaptations of β-cell mass
(BCM) in maternal pancreas.
Both rodent and human β-cells replicate at a low
rate in adulthood (2% per day) (Finegood et al.
1995; Bouwens & Pipeleers, 1998). However, the rise in
circulating placental lactogen and prolactin during rodent
pregnancy has been shown to trigger proliferation of
β-cells around gestational day (GD) 12, which increases
BCM and enhances insulin secretion (Parsons et al. 1992;
Beamish et al. 2017). In rodents, BCM increases by β-cell
replication and hypertrophy, reaching maximal levels
towards late gestation (Rieck & Kaestner, 2010; Beamish
et al. 2017). Elevated maternal oestrogen levels during
pregnancy protect β-cells against apoptosis (Banerjee,
2018). As oestrogen levels drop after parturition, β-cell
apoptosis increases (Scaglia et al. 1995) while β-cell
proliferation decreases (Sorenson & Brelje, 1997; Rieck
& Kaestner, 2010) returning BCM to pre-pregnancy
levels. The compensatory changes in human BCM remain

controversial as the dynamics of BCM expansion are hypothesized to be slightly different from those in mouse
(Baeyens et al. 2016). Nonetheless, the only two human
studies conducted to date have both reported an increase in
β-cell area in pancreata of pregnant women at postmortem
(Van Assche et al. 1978; Butler et al. 2010). These data
suggest that the pancreas of humans, like rodents, should
be able to increase BCM and enhance insulin secretion
during pregnancy. Consequently, in situations where
BCM expansion is suboptimal, GDM can arise (Xiang
et al. 2013). Thus, murine GDM models characterized
by alterations to BCM may relate to the pathology
in humans as both animal models and genome-wide
association studies in humans implicate β-cell dysfunction
as the largest determinant to GDM pathogenesis (Pasek &
Gannon, 2013).
There is currently no reproducibly effective prevention
or reversal intervention for GDM. As rates of GDM are on
the rise, this poses a threat to both the long- and short-term
health of the mother and her offspring. Non-invasive
imaging to analyse expansion of BCM in human
pregnancy has ethical and technical issues making animal
models a desirable alternative for studying the mechanisms
leading to GDM. Although there are inevitable differences
between rodent and human gestation, these differences are
well characterized; consequently, rodents are considered to
be valid models for studies of pregnancy pathophysiology.
One important similarity between rodent and human
gestation is that β-cell dysfunction and insulin resistance
both play an important role in determining metabolic
dysfunction in human and animal models (Pasek &
Gannon, 2013). A useful animal model of GDM would not
demonstrate pre-gestational diabetes but show abnormal
glucose tolerance as pregnancy progressed. As there are
currently few clinically applicable animal models of GDM
(Jawerbaum & White, 2010) that meet these criteria, we
sought to develop a mouse model relevant to the clinical
characteristics of GDM through dietary insult.
It has been established that maternal (F0) dietary
protein restriction (low protein (LP) diet) during early
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life has long-term effects on the endocrine pancreas of the
offspring (F1), which contributes to glucose intolerance
in adulthood (Fernandez-Twinn et al. 2005). Offspring
born to dams fed a LP diet have reduced BCM as neonates
resulting from decreased rates of β-cell proliferation and
increased apoptosis (Petrik et al. 1999). Offspring born
to dams fed a LP diet also have impaired β-cell insulin
release which further contributes to glucose intolerance
in adulthood (Wilson & Hughes, 1997). Using this
well-characterized model, we examined whether female
offspring (F1) of LP diet-fed dams (F0) would develop
glucose intolerance during pregnancy, and whether this
was associated with an altered adaptation of BCM in
maternal endocrine pancreas and/or insulin secretion in
isolated islets of Langerhans. We hypothesized that female
offspring (F1) of LP diet-fed dams would be glucose
intolerant during pregnancy as a result of impaired β-cell
plasticity and reduced insulin secretion.

Methods
Ethical approval

All animal procedures were approved by the Animal Care
Committee of Western University in accordance with
the guidelines of the Canadian Council for Animal Care
(Approval No. 2018-027). Experiments comply with the
policies and regulations of The Journal of Physiology and
with The Journal’s animal ethics checklist.

Animals

Adult (6-week-old) C57Bl/6 male and female mice were
obtained from Charles River Laboratories (Wilmington,
MA, USA) and housed in a temperature-controlled room
with 12 h light/dark cycle at Lawson Health Research
Institute, London, ON, Canada. Water and food were
given ad libitum. Timed pregnancies were accomplished
by establishing mouse oestrous cycling (Byers et al. 2012).
Individual female and male mice were housed together
for mating and separated the following morning. Day
zero of pregnancy was determined by identification of
a vaginal plug. Females were housed individually for
the remainder of pregnancy. F0 females were randomly
allocated to either a control (C, 20% protein, Bio-Serv,
Frenchtown, NJ, USA) or low protein diet (LP, 8%) group
(Fig. 1A), where an increase in carbohydrate in LP diet
(Table 1) yields an isocaloric diet compared to control
chow (Snoeck et al. 1990). F0 dams were fed either
the LP or C diet throughout gestation and lactation. A
total of 24 C and 21 LP litters were used for the study.
Since the primary objective of our study was to produce
a novel rodent model of GDM, we worked only with
female offspring. On postnatal day (PND) 21, all female
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Table 1. Composition (g/100g of diet) of control vs. low protein
rodent chow (Bio-Serv, Frenchtown, NJ, USA)
Component

Control

Low protein

Cornstarch
Casein (88% protein)
Maltodextrin
Sucrose
Soybean oil
Cellulose
Mineral mix
Vitamin mix
L-Cystine
Choline bitartrate
tert-Butylhydroquinone

40.0
22.3
13.2
10.0
4.5
5.0
3.5
1.0
0.3
0.25
0.0014

40.0
8.6
13.2
23.6
4.5
5.0
3.5
1.0
0.3
0.25
0.0014

offspring (F1) were weaned onto C diet for the remainder
of the study while males were euthanized (Fig. 1B). At
maturity (PND42), female offspring (F1) born to dams
fed either a C or a LP diet were randomly allocated
into two subsequent study groups: pregnant (CP, LPP) or
non-pregnant (CNP, LPNP, Fig. 1A). All pregnant grouped
females were time-mated with C diet-fed males, separated
the following morning and housed individually for the
remainder of the experiment. Dams were euthanized
by CO2 asphyxia following an intraperitoneal glucose
tolerance test (IPGTT) on a randomly assigned day of
gestation (gestational day (GD) 9, 12 or 18) for comparison
to non-pregnant age-matched F1 females. Maternal (F1)
blood was collected via cardiac puncture following the
IPGTT, and serum insulin and glucagon were quantified
using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal
Chem, Downers Grove, IL, USA) or Mouse Glucagon
ELISA kit (Crystal Chem). Pancreata were removed
for fixation in 4% paraformaldehyde and sectioned for
histology as previously described (Beamish et al. 2016). At
least three 7 µm-thick cryosections (replicates) were cut
from each pancreas with an interval between each section
>100 µm.
Glucose tolerance tests

An intraperitoneal glucose tolerance test (IPGTT) was
performed on all animals in their home cage prior to
euthanasia as previously described (Chamson-Reig et al.
2009). For the F0 mice, this was 1 month after parturition
while the IPGTTs for the F1 mice were performed at the
assigned gestational day or age for the age-matched group.
Mice were fasted for 4 h with free access to water, injected
intraperitoneally with 5 µl g−1 body weight of 40% glucose
solution (2g kg−1 body weight glucose, Sigma-Aldrich, St
Louis, MO, USA), and blood glucose measured from the
tail at 0, 5, 15, 30, 60, 90 and 120 min using a One Touch
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Ultra2 glucometer. Area under the glucose tolerance curve
was analysed using Prism software (version 5.0, GraphPad
Software Inc., La Jolla, CA, USA).

the primary antibody using 555 (cat. no. A-31570,
RRID:AB_2536180) and 488 fluorophores (cat. no.
A-21206, RRID:AB_141708), respectively, along with
4,6-diamidino-2 phenylindole (DAPI, dihydrochloride,
1:500, Thermo Fisher Scientific, cat. no. D3571,
RRID:AB_2307445) to counterstain nuclei. α-cell mass
(ACM) and BCM were calculated from at least two sections
(replicates) per pancreas (n = 4−7 C and LP animals
per time point) as previously described (Beamish et al.
2017). β-cell size was calculated by taking the sum of the
traced insulin-expressing area and dividing by the total
number of β-cells counted for that section. Islets were
counted per tissue section and further separated by size
into small (less than 5000 µm2 ), medium (between 5000
and 10,000 µm2 ) and large islets (more than 10,000 µm2 ).
Tissue represented both the head and tail of the pancreas
(Chamson-Reig et al. 2006).

Immunohistochemistry

Immunofluorescence
immunohistochemistry
was
performed to co-localize insulin and Ki-67 as a marker for
insulin-immunopositive cells undergoing proliferation
as previously described (Beamish et al. 2017). Slides
were viewed by a blinded technician using a Zeiss
fluorescence Axioskope microscope and cell counting
analysis was performed using ImageJ (Schneider et al.
2012). Every insulin-expressing cell was imaged at 20×
and counted manually. In this study, an ‘islet’ was
considered to contain >5 β-cells, and an extra-islet
‘cluster’ as containing 1–5 β-cells.
Immunofluorescence immunohistochemistry was also
performed to localize insulin (β-cells) and glucagon
(α-cells) for morphometric analysis. Antibodies against
insulin (1:200, anti-mouse, Sigma-Aldrich, cat. no. I2018,
RRID:AB_260137) and glucagon (1:200, anti-rabbit,
Santa Cruz Biotechnology, Dallas, TX, USA, cat.
no. NB110-41547, RRID:AB_805593) were applied to
cryosections and incubated overnight at 4°C. The
following day, secondary antibodies (1:500 Thermo Fisher
Scientific, Waltham, MA, USA) were applied against
A
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Islet isolation and static insulin secretion

Pancreatic islets were isolated from CP (n = 7−9 animals)
and LPP (n = 6−8 animals) pancreata on GD18 by
collagenase V (Sigma-Aldrich) digestion using a modified
sequential dextran gradient protocol (Hehmke et al. 1986;
Cox et al. 2013). Islets were incubated (37°C) overnight
in RPMI medium containing 6.5 mmol l−1 D-glucose,
10% fetal calf serum, and 1% penicillin–streptomycin.

Low Protein
(Pregnant)

F0

F1

Nonpregnant

Pregnant

B

Control
(Pregnant)

F0 pregnancy
Gestation Birth (F1)

Nonpregnant

Pregnant

F1 pregnancy
Lactation

Wean

Maturity

21

42

Gestation

Time
(Days)
0

21

7

14

0 9

12

18

LP or C diet
C diet
Figure 1. Murine model of gestational glucose intolerance
A, schematic flow chart of experimental groups. F0 females were allocated to LP and C diet groups. F1 female
offspring were separated into pregnant, CP and LPP (gestational day 9, 12, 18) and non-pregnant groups (CNP
and LPNP). B, timeline for treatment and sample collection. The F1 offspring were exposed to the low protein (LP)
or control (C) diet during gestation and lactation and weaned onto control diet. At maturity, F1 females were
time-mated with control-fed males. Stars demonstrate time points where an intraperitoneal glucose tolerance test
was performed prior to euthanasia and removal of the pancreas for histology (n = 4−7 animals for each group).
At each time point serum was also collected.
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The following day, islets were pre-incubated in Krebs
buffer solution (KRB, 119 mmol l−1 NaCl, 4.7 mmol l−1
KCl, 25 mmol l−1 NaHCO3 , 2.5 mmol l−1 CaCl2 ·2H2 O,
1.2 mmol l−1 MgSO4 ·7H2 O, 1.2 mmol l−1 KH2 PO4 , 1%
bovine serum albumin, 10 mmol l−1 Hepes) containing
2.8 mmol l−1 glucose for 1 h at 37°C. Groups of 10 islets
of similar size were collected into 1 ml of KRB containing
either 2.8 or 16.7 mmol l−1 glucose (1−3 replicate tubes
per animal). Insulin release was determined in the supernatant after 90 min at 37°C using an Ultra Sensitive Mouse
Insulin ELISA kit (Crystal Chem).

Statistical analysis

The sample size of four to seven animals per variable
in either the LP or C groups was calculated based on
achieving a statistically significant difference with an
expected standard deviation around mean values for BCM
and glucose tolerance of 15% or less based on our previous
studies (Beamish et al. 2017). Each animal presented as a
single unit of analysis (n) for the experiments with the
F0 C- or LP-fed dams and F1 offspring. For comparisons
of litters, each n represented an average value for each
litter. Data are presented as mean ± SEM, with statistics
analysed using GraphPad Prism Version 5.0. An unpaired
two-tailed Student’s t test was used to compare treatment
groups (LP versus C). A two-way ANOVA followed by
Bonferroni’s post hoc test was used for comparison between
treatment groups (LP versus C) at each time point during
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throughout gestation (Fig. 2A). Furthermore, LP diet
consumption had no effect on litter size (Fig. 2B). There
were no differences in the number (Fig. 2C) or ratio
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dams. To test for a possible impact of diet on glucose
homeostasis, an IPGTT was performed at 1 month postpartum. No differences were found between the IPGTT
curves (Fig. 2E) or area under the glucose tolerance curves
(AUC, Fig. 2F) of LP diet-fed females compared to C
diet-fed females.
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gestation. A repeated measures two-way ANOVA followed
by Bonferroni’s post hoc test was used for comparison
of IPGTT curves between treatment groups (LP versus
C) at each time measurement. Animals with fewer than
two fetuses or more than eight were excluded from
statistical analyses. Statistical significance was determined
as P < 0.05.

AUC

J Physiol 597.16

Treatment

Figure 2. Low protein diet during pregnancy does not alter pregnancy characteristics of F0 dams
A–C, low protein (LP) and control (C) diet-fed F0 dams did not statistically differ in mean values for maternal
weight gain (A) (n = 13−14 animals for each group), litter size (B) (n = 24 C litters, 21 LP litters), the number of
male and female offspring (C) (n = 19 C litters, 20 LP litters), or the ratio of male to female offspring (D) (n = 19
C litters, 20 LP litters). E and F, similarly, glucose tolerance (E) and area under the glucose tolerance curve (F) did
not differ (n = 8 C and 7 LP animals for each group). [Colour figure can be viewed at wileyonlinelibrary.com]
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Student’s t test, Fig. 3A) and at PND7 (3.56 ± 0.11 vs.
4.03 ± 0.15g, P < 0.05, unpaired two-tailed Student’s t test,
Fig. 3A). Offspring born to dams fed a LP diet continued to
weigh less with age, demonstrating significantly reduced
body weights compared to controls at weaning, PND21
(8.20 ± 0.34 vs. 9.59 ± 0.36g, P < 0.001, two-way
ANOVA followed by Bonferroni’s post hoc test, Fig. 3A),
which persisted until maturity, PND42 (14.81 ± 0.27 vs.
16.25 ± 0.19g, P < 0.001, two-way ANOVA followed
by Bonferroni’s post hoc test, Fig. 3A). The LPP females
continued to weigh less than CP females (P < 0.001)
throughout their own pregnancy (Fig. 3B). This was
especially apparent during late gestation where the LPP
females gained significantly less weight compared to CP
females (12.78 ± 1.22 vs. 15.24 ± 1.44g, P < 0.001,
two-way ANOVA followed by Bonferroni’s post hoc test,
Fig. 3C). No differences in fetal resorptions were found in
LPP females compared to CP females (Fig. 3D).
Offspring of low protein-fed mothers are glucose
intolerant during their own gestation

There were no significant differences in fasting blood
glucose levels between LPP and CP females at any time
point during gestation or between CNP and LPNP females.
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Furthermore, no differences in blood glucose levels or
AUC were found for non-pregnant (Fig. 4A), GD9 (Fig.
4B) or GD12 (Fig. 4C) offspring born to dams fed a LP or
C diet when subjected to an IPGTT. By GD18, LPP females
had significantly higher blood glucose levels compared to
CP at 5 min (18.88 ± 2.22 vs. 10.73 ± 0.97 mmol l−1 ,
P < 0.001, repeated measures two-way ANOVA followed
by Bonferroni’s post hoc test) but no significant difference
was found in AUC (Fig. 4D).

Weight (g)

4242

Day of Pregnancy

Figure 3. Offspring of LP-fed dams show altered pregnancy characteristics
A, offspring of LP-fed mothers weighed less than controls by weaning (postnatal day (PND) 21, n = 13−22 litters
for each group). B and C, LPP females weighed less than CP females throughout gestation (B) and put on less
weight at late gestation (C) compared to CP females (n = 25 CP and 24 LPP animals). D, the number of fetuses did
not differ throughout gestation between CP and LPP females (n = 7−22 animals for each group). ∗∗∗ P < 0.001,
∗∗ P < 0.01, ∗ P < 0.05, LP vs. C. [Colour figure can be viewed at wileyonlinelibrary.com]
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To determine whether the reduced BCM was due
to decreased β-cell proliferation, we used immunohistochemistry to identify insulin-containing cells
co-localized with the DNA synthesis marker Ki-67.
Proliferating, insulin-expressing cells were identified in
both clusters and islets of offspring born to LP- and C-fed
dams. β-cell proliferation increased during pregnancy in
CP females but was significantly reduced in LPP females
on GD12 (2.11 ± 0.31 vs. 3.48 ± 0.66% Ki67+ Ins+ /Ins+
(total), P < 0.05, two-way ANOVA followed by
Bonferroni’s post hoc test, Fig. 5C). The reduced β-cell
proliferation at GD12 was specific to small β-cell
clusters (3.03 ± 1.14 vs. 6.47 ± 1.22% Ki67+ Ins+ /Ins+
(clusters), P < 0.05, two-way ANOVA followed by
Bonferroni’s post hoc test, Fig. 5D). Representative images
of proliferating β-cells (% Ki67+ Ins+ ) in non-pregnant,

GD12 and GD18 animals are shown in Fig. 6. We found
no evidence of co-localized insulin/TUNEL cells (TUNEL,
terminal deoxynucleotidyl transferase dUTP nick end
labeling, staining detects apoptosis) during gestation
(GD12 and 18) in either the CP or the LPP females.
Although there was no effect of treatment on the ratio
of α- to β-cells, there was a change with day of pregnancy
(P < 0.001, two-way ANOVA, Fig. 7A). Mean islet size
was reduced at GD18 in LPP females (4323 ± 463 vs.
7967 ± 1542 µm2 , P < 0.05, two-way ANOVA followed by
Bonferroni’s post hoc test, Fig. 7B); however, there were no
differences in β-cell size (Fig. 7C). Nonetheless, there was a
reduction in the number of small islets in LPP compared to
CP females at GD9 (3.80 ± 0.93 vs. 12.50 ± 1.43, P < 0.001,
two-way ANOVA followed by Bonferroni’s post hoc test,
Fig. 7D), GD12 (5.92 ± 1.27 vs. 11.33 ± 2.32, P < 0.05, twoway ANOVA followed by Bonferroni’s post hoc test, Fig.
7E), and GD18 (7.90 ± 1.39 vs. 17.88 ± 2.98, P < 0.001,
two-way ANOVA followed by Bonferroni’s post hoc test,
Fig. 7F). No differences in distribution of islet sizes were
seen in non-pregnant animals (Fig. 7G).
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AUC

P < 0.01, two-way ANOVA followed by Bonferroni’s
post hoc test, Fig. 5B).

Blood glucose (mmol . L–1)

J Physiol 597.16

Time (minutes)

Figure 4. Offspring of low protein-fed mothers are glucose intolerant during their own gestation
Blood glucose (mmol l−1 ) and area under the glucose tolerance curve (AUC) data from intraperitoneal glucose
tolerance tests performed on offspring from low protein (LP, continuous lines) and control-fed (C, dashed lines)
mothers. A–C, there were no differences between blood glucose and AUC levels of non-pregnant (A) (n = 6 CNP
and 5 LPNP animals), gestational day (GD) 9 (B) (n = 4 animals for each group), or GD12 (C) (n = 6 animals for
each group) LPP and CP females. D, LPP females displayed higher blood glucose levels on GD18 when compared
to CP females. However, no differences were found in AUC values (n = 7 CP and 4 LPP females). ∗∗∗ P < 0.001, LP
vs. C. [Colour figure can be viewed at wileyonlinelibrary.com]
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To assess β-cell function, we measured insulin secretion of
isolated pancreatic islets from GD18 CP and LPP females.
Levels of insulin were similar between LPP and CP females
after 90 min in medium containing 2.8 mmol l−1 glucose
(Fig. 8A). However, islets from LPP females secreted less
insulin in the presence of 16.7 mmol l−1 glucose than
CP females (0.22 ± 0.04 vs. 0.49 ± 0.07 ng ml−1 islet−1 ,
P < 0.01, two-way ANOVA followed by Bonferroni’s
post hoc test, Fig. 8A). To confirm these findings in
vivo, serum insulin was quantified from blood drawn by
cardiac puncture following the IPGTT. Confirming the
in vitro findings, LPP females had lower serum insulin
levels compared to CP females on GD18 (0.57 ± 0.10 vs.
1.34 ± 0.25 ng ml−1 , P < 0.05, unpaired two-tailed
Student’s t test, Fig. 8B). Although serum glucagon levels
appeared to be lower in LPP females on GD18, there were
no significant differences found when compared to CP
females (Fig. 8C).
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This study proposes a novel mouse model of gestational
glucose intolerance in which metabolic impairments
are restricted to late gestation, as is seen clinically in
human GDM. Epidemiological studies in humans have
demonstrated strong associations between poor fetal
growth, for instance as encountered in times of famine,
and susceptibility to metabolic syndrome in adult life
(Hales, 1997a,b). These observations have been replicated
in maternal malnutrition studies in animals, resulting in
permanent changes in tissue composition and cell size in
the offspring during adulthood, ultimately contributing
to the metabolic syndrome phenotype (Hales et al. 1996).
In agreement with the concept of developmental origins of
health and disease (Barker & Osmond, 1986), we show in
this study that the intrauterine environment influences
the risk of metabolic disease in offspring later in life.
We previously showed that offspring of LP-fed mothers
had reduced BCM and developed glucose intolerance in
adulthood (Cox et al. 2013). In this study we investigated
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Offspring of low protein-fed mothers show
gestational β-cell dysfunction in vitro and in vivo

Alpha cell mass (mg)
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Day of Pregnancy

Figure 5. Offspring of LP-fed mothers have altered pancreatic morphology during pregnancy compared
to controls
A and B, β-cell mass expansion (A) and α-cell mass expansion (B) were impaired in LPP females compared to CP
females on GD18 (n = 4−6 animals for each group, 2−3 replicates for each animal). C, total β-cell proliferation
was reduced during gestation in LPP females on GD12 (n = 4−7 animals for each group, at least 2 replicates for
each animal). D, β-cell proliferation was reduced in clusters during gestation in LPP females on GD12 (n = 4−7
animals for each group, at least 2 replicates for each animal). ∗∗ P < 0.01, ∗ P < 0.05, LP vs. C.
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whether offspring of LP-fed mothers would have a predisposition to glycaemic dysfunction during pregnancy
and the underlying pancreatic physiology that might
contribute towards this phenotype. Overall, LP diet did
not impact the pregnancy characteristics of F0 dams
as no differences in maternal weight gain, litter size,
sex of offspring, or glucose homeostasis were found.
Furthermore, it has previously been shown that isolated
islets from pregnant LP-fed rats had a similar response
to physiological glucose concentrations compared to
controls (Milanski et al. 2005), while another study
concluded that a short period of LP-diet consumption did
not alter total area under the glucose and insulin curves
during a GTT or basal serum glucose measurements,
indicating preservation of pancreatic function (Souza Dde
et al. 2012). Although this is being extrapolated from
rats, we would not anticipate that LP-fed dams in our
study would demonstrate gestational glucose intolerance
and provide a model for GDM. However, the phenotype
was altered in offspring of LP-fed mothers showing a
reduced body weight at birth and PND7, which persisted
with age and throughout their own pregnancy. Although
we do not have data on visceral adipose tissue in our
study, a previous study in our laboratory found no
differences in visceral adipose tissue between offspring
of LP- and C-fed rats at 130 days of age (Chamson-Reig

et al. 2009). Furthermore, because we are using young,
pre-oestropausal mice in our study, we anticipate that
there would be no differences in visceral adipose tissue present in our model at this age. In humans, postmenopausal
women begin to have increased visceral fat accrual (Camhi
et al. 2011). Therefore, potential differences in visceral
adipose tissue in our model might only be seen at
oestropause, which in rodents is at 9–12 months of age
(Koebele & Bimonte-Nelson, 2016).
In addition to the physical differences found between
offspring of LP- and C-fed mothers, we found maternal
glucose intolerance when LPP females were subjected to
an IPGTT at GD18. In comparison to our findings, the
authors of a similar study using the LP diet model in
rats stated that their model did not promote the onset of
GDM (Ignácio-Souza et al. 2013). However, this claim
is made based on AUC data, for which our data are
comparable on GD18. Nevertheless, the authors did not
include their IPGTT curves, which is where we noted
abnormally elevated maternal blood glucose levels in the
LPP females. Previous studies found no differences in
fasting blood glucose levels in young offspring (PND1,
7, 14 and 30) of LP- and C-fed mothers (Cox et al. 2010).
Furthermore, LPNP female rodents did not demonstrate
glucose intolerance until later in adulthood (Blondeau &
Breant, 2005; Chamson-Reig et al. 2009; Cox et al. 2010),
GD12

NP
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Figure 6. LPP females show reduced β-cell replication at GD12 compared to CP females
Representative immunofluorescence images demonstrating insulin (red), Ki-67 (yellow) and nuclei (DAPI, blue)
staining of CNP, LPNP, CP and LPP females (at GD12 and GD18). White arrows demonstrate co-localized insulin
and Ki-67 cells as an example of proliferating β-cells within an islet. Scale bar represents 50 µm.
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Figure 7. LPP females have an altered distribution of islet sizes, contributing to a reduced mean islet
size and BCM expansion at late gestation
A, α- to β-cell ratio varies with day of pregnancy but not between dietary groups. B, mean islet size was reduced
in LPP females compared to CP females on GD18. C, however, this was not due to a change in β-cell size. D–G,
the number of small islets was reduced in LPP females on GD9 (D), GD12 (E) and GD18 (F) but not in LPNP females
(G) (n = 4−6 animals for each group, 2−3 replicates for each animal). ∗∗∗ P < 0.001, ∗ P < 0.05, LP vs. C.
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pancreas histology postpartum using our animal model
of GDM could prove insightful.
Consistent with previous findings (Xue et al. 2010;
Beamish et al. 2017), we observed that CP females were
able to expand BCM to compensate for insulin resistance
in pregnancy. However, BCM expansion was impaired
in LPP females compared to CP females, as has been
postulated to occur in human GDM (Van Assche et al.
1979; Huang et al. 2009; Rieck & Kaestner, 2010). In

G

and the onset in young adults in this study is likely to have
been precipitated by the metabolic stress of pregnancy
since there were no differences in glucose tolerance
between CNP and LPNP. Clinically, since prior GDM
increases the risk of the mother developing subsequent
T2DM (Heida et al. 2015), it is plausible that the LPP
females could prematurely develop glucose intolerance
following pregnancy compared to non-pregnant animals.
Future studies investigating metabolic differences and
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Treatment

Figure 8. Offspring of low protein-fed mothers show gestational β-cell dysfunction in vitro and in vivo
A, glucose-stimulated insulin secretion was reduced on GD18 from isolated pancreatic islets from LPP females
(n = 6−9 animals for each group, 1−3 replicates for each animal). B, serum insulin levels of LPP females were
reduced on GD18 (n = 7 animals for each group). C, serum glucagon levels did not differ between CP and LPP
females on GD18 (n = 5 animals for each group). ∗∗ P < 0.01, ∗ P < 0.05, LP vs. C.
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agreement with our previous work, the expansion of
BCM during pregnancy was associated with increased
β-cell proliferation (Beamish et al. 2017), which was
significantly reduced in LPP females. This was particularly
apparent within the small extra-islet endocrine clusters
which we have previously shown to be a source of β-cell
progenitors (Beamish et al. 2016). This suggests that the
proliferation of progenitors or their differentiation into
functional β-cells might be impaired in LPP females.
Reduced β-cell proliferation in LPP females contributed
to a reduced mean islet size at GD18, consequently
contributing to reduced BCM expansion. Although there
were no differences in β-cell size in LPP versus CP females,
there were fewer small islets in LPP females at GD9, 12
and 18 compared to CP females. Since there was a relative
increase in large islets of CP females at GD18 compared to
GD9, we postulate that β-cell replication within small islets
facilitates islet growth into medium and large-sized islets
as gestation progresses (GD18). This further contributed
to increased BCM expansion in CP females at GD18.
However, since LPP females had fewer small islets, there
were fewer available to facilitate an adaptive expansion
of BCM at GD18. Since there were no differences in
islet size distribution in the LPNP versus CNP animals,
these differences were attributed to the metabolic state
of pregnancy. Although increased β-cell apoptosis is seen
in offspring of LP-fed mothers (Petrik et al. 1999), here
we found no evidence of apoptosis within β-cells of LPP
or CP females during a subsequent gestation. Thus, this
excludes the possibility of β-cell apoptosis contributing
to the reduced capacity for BCM expansion in LPP
females. These results are in agreement with the findings
of another animal model of maternal glucose intolerance
during gestation, in which the authors also reported that
β-cell apoptosis did not contribute to the impairment of
BCM expansion (Xu et al. 2015). These results could be
attributed to the contribution of the protein survivin,
which normally becomes upregulated during gestation
and acts as an inhibitor of apoptosis via epidermal
growth factor-receptor signalling (Hakonen et al. 2014).
In addition to the dynamics of BCM investigated in this
study, we are the first to report on α-cell dynamics in the
pancreas during rodent pregnancy. Although there was
no effect of treatment on the ratio of α- to β-cells, there
was a change with day of pregnancy. Further to reduced
BCM, we found a relative decrease in ACM in CP females
throughout gestation when compared to CNP females.
While CP females replenished ACM by GD18, this was not
found in LPP females. There is evidence through lineage
tracing of α-cells that they can replenish β-cells following
β-cell loss or during β-cell stress via trans-differentiation
(Thorel et al. 2010; Ye et al. 2015). These findings could
implicate α- to β-cell trans-differentiation as a contributor
to expanded BCM during pregnancy, which might be
impaired in LPP females.
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We also examined β-cell functional capacity in our
model, since β-cell dysfunction is a key feature of the
pathophysiology of GDM (Saisho et al. 2010). Although
insulin release from isolated islets harvested in late
pregnancy in response to basal glucose concentration
did not differ between dietary groups, glucose-stimulated
insulin secretion (GSIS) was significantly decreased in LPP
females. These results are in agreement with other reports
in which impaired GSIS was found in islets of offspring of
LP-fed mothers as a result of mitochondrial dysfunction
in β-cells (Theys et al. 2009). Future studies investigating
mitochondrial β-cell dysfunction in our model would be
insightful as women with GDM demonstrate increased
oxidative stress, which has been suggested to contribute
to β-cell dysfunction in GDM (Zhu et al. 2015). We
confirmed our in vitro findings in vivo, showing that
LPP females had reduced serum insulin levels at GD18
compared to CP females. These data supported our
hypothesis and implicate β-cell dysfunction both in
vivo and in vitro at late gestation in our model of
gestational glucose intolerance. Therefore, in our model a
combination of reduced BCM and impaired GSIS most
likely contributed to the glucose intolerance seen in
LPP females. Since our study was limited to changes in
pancreas histology, we cannot eliminate the possibility that
insulin resistance at the level of target tissues contributed
to glucose intolerance during pregnancy in offspring
of LP-fed mothers. However, this has previously been
shown to occur only in late adulthood (130 days) and
not within the young adult mice used in these studies
(Chamson-Reig et al. 2009). Nevertheless, a major strength
of our study was the ability to reproduce gestational
glucose intolerance during pregnancy complications such
as GDM in which glucose intolerance is not diagnosed
until late gestation. In our study, glucose intolerance
was restricted to GD18 and was not seen in the
non-pregnant state as has been shown in other models
of gestational glucose intolerance (Ignácio-Souza et al.
2013). Furthermore, additional animal models of diabetes
in pregnancy that demonstrate pre-gestational obesity
and diabetes (Holemans et al. 2004; Liang et al. 2010)
display glucose intolerance prior to conception, which
is not a true diagnosis of clinical GDM (Kim et al.
2010). Animal models utilizing chemical destruction of
β-cells are widely used for modelling pre-gestational
and gestational diabetes; however, these models more
accurately resemble pre-gestational type-1 diabetes as
opposed to the characteristics of insulin resistance seen
in conditions such as GDM (Caluwaerts et al. 2003).
Therefore, in comparison to other models, our model
of fetal programming of gestational glucose intolerance
via dietary insult more accurately demonstrates the
hyperglycaemic state of GDM, which occurs only at
late gestation. Although our dietary insult involves
protein restriction during development, the LP diet is
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made isocaloric to the control diet through increased
carbohydrate, which prompts the question of whether
our findings are due to the effects of reduced protein
or increased carbohydrate intake. However, the increase
in carbohydrate content represents only a 20% increase
compared to the more prominent 60% reduction of
protein (20% casein versus 8%), which suggests that
the glycaemic dysfunction and impairments in pancreas
histology and function in our model are more likely the
result of reduced protein (Chamson-Reig et al. 2009).
Susceptibility to developing GDM arises from a complex
combination of both polygenetic and environmental
factors. Taking this into account, the developmental
programming of adult metabolism utilized in this mouse
model of glycaemic imbalance during pregnancy does
not reproduce the predominant predisposing causes of
human GDM, which include pre-gestational obesity and
excessive gestational weight gain (Farrar, 2016; Melchior
et al. 2017). Nonetheless, there are a number of anatomical
and metabolic similarities including a failure to adequately
increase BCM during pregnancy and impaired GSIS in
late gestation. Postmortem studies of human pancreata
obtained from pregnant individuals confirmed an increase
in endocrine mass during healthy pregnancies compared
to the non-pregnant state (Van Assche et al. 1978; Butler
et al. 2010), and it has been suggested that failure to
adaptively increase BCM might contribute to the risk
of GDM in humans (Xiang et al. 2013). Thus, further
research efforts should focus on molecular mechanisms
(i.e. signalling via prolactin and/or oestrogen receptors)
leading to reduced BCM expansion during gestation
so that targeted interventions can be implemented. In
conclusion, the model of hyperglycaemia in pregnancy
described in this study could prove useful in evaluating
pharmacological interventions aimed at safely increasing
BCM or GSIS during pregnancy.
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